After Pausing Its I.P.O., Oura Jumps on the GLP-1 Hype With Weight-Loss Tracking
Trending Topics Jakob Steinschaden
Oura is adding weight-loss shot tracking to its ring and opening the feature in the EU. It’s doing that while its planned Nasdaq listing stays on ice.
Based on reporting by Trending Topics, Jakob Steinschaden — read the original for the full story.
Summary, retelling and take written by AI under human oversight; images are AI-generated illustrations. How we work · Report an error
Oura is pushing deeper into health tracking, and the timing is doing a lot of work. The Finnish ring maker is bringing its GLP-1 Insights feature, plus new blood pressure and breathing tools in Health Radar, to more than 30 additional markets, including the European Union. The GLP-1 part is aimed at people using drugs like Ozempic or Wegovy, whether they take them as injections or pills.
The idea is simple enough: users log their dose, schedule, side effects such as nausea or appetite changes, and their weight. Oura then mixes that with the ring’s own sleep, activity, recovery and stress data to show how treatment lines up with the rest of the body over time. It’s already live in the United States, India and the United Arab Emirates, and works with the Oura Ring Gen3 and newer models. Oura is careful to say the ring is not a medical device and does not replace a doctor.
That caution matters, because the company is selling insight, not measurement. The ring does not detect GLP-1 drugs in the blood. It also does not tell users how much to take. What it does offer is a long-running log that could be useful in a clinic visit, especially as GLP-1 drugs spread and more people end up juggling side effects, weight changes and several different apps.
Health Radar extends that pitch beyond weight loss. Blood Pressure Signals looks at the ring’s optical pulse data in the background for patterns that may point to strain on the heart and circulation. Nighttime BP checks whether blood pressure dips during sleep the way it normally should, while Nighttime Breathing tracks breathing regularity and disturbances over a 30-day period. Oura says the system was developed with more than 40 in-house physicians and scientists.
All of this lands while the company’s biggest plan is still paused. Oura had wanted to raise up to $2.2 billion on Nasdaq and reach a valuation of around $14 billion, but shelved the offering despite strong demand, citing uncertainty in the IPO market. Revenue in the first nine months of its fiscal year rose 74 percent to $1.21 billion, and it now counts 5.7 million paying members. So the business is humming. The stock market, less so.
My take — AI-written commentary, not fact-checked reporting
This is classic wearable-industry behavior: when the ring stops being a gadget and starts being a diary, everybody calls it innovation. Oura is smart to chase GLP-1 users, but the real product here is not health science; it’s retention. The open question is how many people want a tiny wellness assistant and how many just want one less app to nag them.
Read more about this at: Trending Topics